Modulation of gene expression rather than monoamine oxidase inhibition: (-)-Deprenyl-related compounds in controlling neurodegeneration

Neurology

Volumn 47, Issue 6 SUPPL. 3, 1996, Pages

  Tatton, W G ^a   Chalmers Redman, R M E ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BROFAROMINE; CLORGYLINE; IPRONIAZID; MOFEGILINE; MONOAMINE OXIDASE INHIBITOR; N (2 AMINOETHYL) 4 CHLOROBENZAMIDE; NIALAMIDE; NITRIC OXIDE SYNTHASE; PHENELZINE; PROTEIN BCL 2; SELEGILINE; SEMICARBAZIDE DERIVATIVE; SUPEROXIDE DISMUTASE; TRANYLCYPRAMINE; UNCLASSIFIED DRUG;

APOPTOSIS; DOPAMINERGIC TRANSMISSION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; GENE; GENE EXPRESSION REGULATION; HUMAN; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; NERVE CELL NECROSIS; NERVE DEGENERATION; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW;

ANIMALS; GENE EXPRESSION; HUMANS; MONOAMINE OXIDASE; NERVE DEGENERATION; SELEGILINE;

EID: 0029731378     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (205)

1. Shih JC, Zhu QS, Grimsby J, Chen K. Identification of human monoamine oxidase (MAO) A and B gene promoters J Neural Transm 1994;41:27-33.
2. Bach AWJ, Lan NC, Johnson DL, et al. cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. Proc Natl Acad Sci USA 1988;85:4934-4938.
3. Shih JC. Molecular basis of human MAO A and B. Neuropsychopharmacology 1991;4:1-7.
4. Mayanil CSK, Baquer NK. Comparison of the properties of semipurified mitochondrial and cytosolic monoamine oxidases from rat brain. J Neurochem 1984;43:906-912.
5. Westlund KN, Krakower TJ, Kwan SW, Abell CW. Intracellular distribution of monoamine oxidase A in selected regions of rat and monkey brain and spinal cord. Brain Res 1993;612: 221-230.
6. Richards JG, Saura J, Ulrich J, Da-Prada M. Molecular neuroanatomy of monoamine oxidases in human brainstem. Psychopharmacology (Berl) 1992;106(suppl):S21-S23.
7. Vincent SR. Histochemical localization of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine oxidation in the mouse brain Neuroscience 1989;28:189-199.
8. Demarest KT, Smith DJ, Azzaro AJ. The presence of the type A form of monoamine oxidase within nigrostriatal dopamine-containing neurons. J Pharmacol Exp Ther 1980;215:461-468.
9. Westlund KN, Denney RM, Kochersperger LM, Rose RM, Abell CW. Distinct monoamine oxidase a and b populations in primate brain. Science 1985;230:181-183.
10. Westlund KN, Denney RM, Rose RM, Abell CW. Localization of distinct monoamine oxidase a and monoamine oxidase b cell populations in human brainstem. Neuroscience 1988;25: 439-456.
11. Konradi C, Kornhuber L, Froelich L, et al. Demonstration of monoamine oxidase-A and -B in the human brainstem by a histochemical technique. Neuroscience 1989;33:383-400.
12. Gerlach M, Riederer P, Youdim MB. The molecular pharmacology of L-deprenyl. Eur J Pharmacol 1992;226:97-108.
13. Waldmeier PC, Felner AE. Deprenil, loss of selectivity for inhibition of b-type MAO after repeated treatment. Biochem Pharmacol 1978;27:801-806.
14. Birkmayer W, Riederer P, Ambrozi L, Youdim MBH. Implications of combined treatment with 'madopar' and L-deprenyl in Parkinson's disease. Lancet 1977;1:439-443.
15. Glover V, Sandler M, Owen F. Dopamine is a monoamine oxidase B substrate in man. Nature 1977;265:80-81.
16. Paterson IA, Juorio AV, Boulton AA. Possible mechanism of action of deprenyl in parkinsonism [letter]. Lancet 1990;336: 183.
17. Fang J, Yu PH. Effect of L-deprenyl, its structural analogues and some monoamine oxidase inhibitors on dopamine uptake. Neuropharmacology 1994;33:763-768.
18. Olanow CW. Oxidative reactions in Parkinson's disease Neurology 1990;40:32-37.
19. Cohen G. Oxygen radicals and Parkinson's disease. Neurology 1988;38:130-135.
20. Carlsson A, Fornstedt B. Possible mechanisms underlying the special vulnerability of dopaminergic neurons. Acta Neurol Scand 1991;84:16-18.
21. Youdim MB, Lavie L, Riederer P. Oxygen free radicals and neurodegeneration in Parkinson's disease. Ann N Y Acad Sci 1994;738:64-68.
22. Jellinger K, Kienzl E, Rumpelmair G, Riederer P, Stachelberger H. Iron-melanin complex in substantia nigra of parkinsoman brains: an x-ray microanalysis. J Neurochem 1992; 59:1168-1171.
23. Sofic E, Paulus W, Jellinger K, Riederer P, Youdim MB, Amit T. Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem 1991;56:978-982.
24. Good PF, Olanow CW, Perl DP. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study. Brain Res 1992;593:343-346.
25. Youdim MB, Ben-Shachar D, Riederer P. The enigma of neuromelanin in Parkinson's disease substantia nigra. J Neural Transm Suppl 1994;43:113-122.
26. Gerlach M, Ben SD, Riederer P, Youdim MB. Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem 1994;63:793-807.
27. Sengstock GJ, Olanow CW, Dunn AJ, Arendash GW. Iron induces degeneration of nigrostriatal neurons. Brain Res Bull 1992;28:645-649.
28. Ben-Shachar D, Youdim MB. Intranigral iron injection induces behavioral and biochemical "parkinsonism" in rats. J Neurochem 1991;57:2133-2135.
29. Birkmayer W, Riederer P, Youdim MBH, Linauet W. The potentiation of the anti-akinetic effect of L-dopa treatment by an inhibitor of MAO-B, L-deprenyl. J Neural Transm 1975; 36:303-336.
30. Brannan T, Yahr MD. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease. Ann Neurol 1995;37:95-98.
31. Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995;38:771-777.
32. Parkinson SG. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. NEJM. 1993;328:176-183.
33. Burke WJ, Roccaforte WH, Wengel SP, Bayer BL, Ranno AE, Willcockson NK. L-Deprenyl in the treatment of mild dementia of the Alzheimer type: results of a 15-month trial. J Am Geriatr Soc 1993;41:1219-1225.
34. Alhainen K, Riekkinen P. Combination of tacrine and selegiline in Alzheimer's disease: an open pilot study. 1995.
35. Martignoni E, Bono G, Blandini F, Sinforiani E, Merlo P, Nappi G. Monoamines and related metabolite levels in the cerebrospmal fluid of patients with dementia of Alzheimer type: influence of treatment with L-deprenyl. J Neural Transm Park Dis Dement Sect 1991;3:15-25.
36. Mangoni A, Grassi MP, Frattola L, et al. Effects of a MAO-B inhibitor in the treatment of alzheimer disease. Eur Neurol 1991;31:100-107.
37. Marin DB, Bierer LM, Lawlor BA, et al. L-Deprenyl and physostigmine for the treatment of Alzheimer's disease. Psychiatry Res. 1995;58:181-189.
38. Schneider LS, Olin JT, Pawluczyk S. A double-blind cross-over pilot study of L-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease. Am J Psychiatry 1993;150:321-323.
39. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Ann Neurol 1996;39:29-36.
40. Schulzer M, Mak E, Calne DB. The antiparkinsonism efficacy of deprenyl derives from transient improvement which is likely to be symptomatic. Ann Neurol 1992;32:795-798.
41. Knoll J, Yen TT, Miklya I. Sexually low performing male rats die earlier than their high performing peers and (-)deprenyl treatment eliminates this difference. Life Sci 1994;54:1047-1057.
42. Kitani K, Kanai S, Sato Y, Ohta M, Ivy GO, Carrillo MC. Chronic treatment of (-)deprenyl prolongs the life span of male Fischer 344 rats: further evidence. Life Sci 1993;52: 281-288.
43. Yen TT, Knoll J. Extension of lifespan in mice treated with Dinh lang (Policias fruticosum L.) and (-)deprenyl. Acta Physiol Hung 1992;79:119-124.
44. Milgram NW, Racine RJ, Nellis P, Mendonca A, Ivy GO. Maintenance on L-deprenyl prolongs life in aged male rats. Life Sci 1990;47:415-420.
45. Freisleben HJ, Lehr F, Fuchs J. Lifespan of immunosuppressed NMRI-mice is increased by deprenyl. J Neural Transm Suppl 1994;41:231-236.
46. Lees AJ and the Parkinson's Disease Research Group of the United Kingdom. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. BMJ 1995; 311:1602-1607.
47. Gerlach M, Riederer P, Vogt H. Effect of adding selegeline to levodopa in early, mild Parkinson's disease: "on treatment" rather than intention to treat analysis should have been used [letter]. BMJ 1996;312:704.
48. Jellinger KA. Effect of adding selegeline to levodopa in early, mild Parkinson's disease: causes of death need confirmation [letter]. BMJ 1996;312:704-705.
49. Maki-Ikola O, Kilkku O, Heinonen E. Effect of adding selegiline to levodopa in early, mild Parkinson's disease: other studies have not shown increased mortality [letter]. BMJ 1996;312:704-705.
50. Olanow CW, Godbold JH, Koller W. Effect of adding selegiline to levodopa in early, mild Parkinson's disease: patients taking selegiline may have received more levodopa than necessary [letter]. BMJ 1996;312:702-703.
51. Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 1984;311:467-469.
52. Langston JW, Irwin I, Langston EB, Forno LS. Pargyline prevents 1 methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in primates. Science 1984;225:1480-1482.
53. Mytilineou C, Cohen G. Deprenyl protects dopamine neurons from neurotoxic effect of 1-methyl-4-phenylpyridinium ion. J Neurochem 1985;45:1951-1953.
54. Tatton WG, Greenwood CE. Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J Neurosci Res 1991;30:666-672.
55. Tatton WG, Seniuk NA, Ju WYH, Ansari KS. Reduction of nerve cell death by deprenyl without monoamine oxidase inhibition. In: Lieberman A, Olanow W, Youdim M, Tipton K, eds. Monoamine oxidase inhibitors in neurological diseases. New York: Raven, 1993:217-248.
56. Finnegan KT, Skratt JJ, Irwin I, DeLanney LE, Langston JW. Protection against DSP-4-induced neurotoxicity by deprenyl is not related to its inhibition of MAO-B. Eur J Pharmacol 1990;184:119-126.
57. Yu PH, Davis BA, Fang J, Boulton AA. Neuroprotective effects of some monoamine oxidase-B inhibitors against DSP-4-induced noradrenaline depletion in the mouse hippocampus. J Neurochem 1994;63:1820-1828.
58. Zhang X, Yu PH. Depletion of NOS activity in the rat dentate gyms neurons by DSP-4 and protection by deprenyl. Brain Res Bull 1995;38:307-311.
59. Tatton WG. Selegiline ((-)-deprenyl) can mediate neuronal rescue rather than neuronal protection. Mov Dis 1993;8:S20-S30.
60. Beilharz EJ, Williams CE, Dragunow M, Sirimanne ES, Gluckman PD. Mechanisms of delayed cell death following hypoxic-ischemic injury in the immature rat: evidence for apoptosis during selective neuronal loss. Brain Res Mol Brain Res 1995;29:1-14.
61. Hassouna I, Wickert H, Zimmermann M, Gillardon F. Increase in bax expression in substantia nigra following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment of mice. Neurosci Lett 1996;204:85-88.
62. +) in ventral mesencephalic-striatal co-culture in rat. Neurosci Lett 1994;170:191-194.
63. Dipasquale B, Marini AM, Youle RJ. Apoptosis and DNA degradation induced by 1-methyl-4-phenylpyridinium in neurons. Biochem Biophys Res Commun 1991;181:1442-1448.
64. Oo TF, Henchcliffe C, Burke RE. Apoptosis in substantia nigra following developmental hypoxic-ischemic injury. Neuroscience 1995;69:893-901.
65. Rossiter JP, Riopelle RJ, Bisby MA. Axotomy-induced apoptotic cell death of neonatal rat facial motoneurons: time course analysis and relation to NADPH-diaphorase activity. Exp Neurol 1996;138:33-44.
66. Berkelaar M, Clarke DB, Wang YC, Bray GM, Aguayo AJ. Axotomy results in delayed death and apoptosis of retinal ganglion cells in adult rats. J Neurosci 1994;14:4368-4374.
67. Garcia VE, Gorczyca W, Darzynkiewicz Z, Sharma SC. Apoptosis in adult retinal ganglion cells after axotomy. J Neurobiol 1994;25:431-438.
68. Rabacchi SA, Bonfanti L, Liu XH, Maffei L. Apoptotic cell death induced by optic nerve lesion in the neonatal rat. J Neurosci 1994;14:5292-5301.
69. Rukenstein A, Rydel RE, Greene LA. Multiple agents rescue PC12 cells from serum-free cell death by translation- and transcription-independent mechanisms. J Neurosci 1991;11: 2552-2563.
70. Barber AJ, Paterson IA, Gelowitz DL, Voll CL. Deprenyl protects rat hippocampal pyramidal cells from ischemic insult [abstract]. Soc Neurosci Abstr 1993;19:1646.
71. Zeng YC, Bongrani S, Bronzetti E, et al. Effect of long-term treatment with L-deprenyl on the age-dependent microanatomical changes in the rat hippocampus. Mech Ageing Dev 1995;79:169-185.
72. Roy E, Bedard PJ. Deprenyl increases survival of rat foetal nigral neurones in culture. Neuroreport 1993;4:1183-1186.
73. Koutsilieri E, O'Callaghan JF, Chen TS, Riederer P, Rausch WD. Selegiline enhances survival and neunte outgrowth of MPP(+)-treated dopaminergic neurons. Eur J Pharmacol 1994;269.
74. + dopaminergic toxicity. J Neural Transm Gen Sec 1995;100:53-61.
75. Hao R, Ebadi M, Pfeiffer RF. Selegiline protects dopaminergic neurons in culture from toxic factort(s) present in the cerebrospinal fluid of patients with Parkinson's disease. Neurosci Lett 1995;200:77-80.
76. Knollema S, Aukema W, Horn H, Korf J, TerHorst GJ. L-Deprenyl reduces brain damage in rats exposed to transient hypoxia-ischemia. Stroke 1995;26:1883-1887.
77. Salo PT, Tatton WG. Deprenyl reduces the death of motor-neurons caused by axotomy. J Neurosci Res 1992;31:394-400.
78. Ansari KS, Yu PH, Kruck TP, Tatton WG. Rescue of axotomized immature rat facial motoneurons by R(-)-deprenyl: stereospecificity and independence from monoamine oxidase inhibition. J Neurosci 1993;13:4042-4053.
79. Oh C, Murray B, Bhattacharya N, Holland D, Tatton WG. (-)-Deprenyl alters the survival of adult murine facial motoneurons after axotomy: increases in vulnerable C57BL strain but decreases in motor neuron degeneration mutants. J Neurosci Res 1994;38:64-74.
80. Ju WY, Holland DP, Tatton WG. (-)-Deprenyl alters the time course of death of axotomized facial motoneurons and the hypertrophy of neighboring astrocytes in immature rats. Exp Neurol 1994;126:233-246.
81. Zhang F, Richardson PM, Holland DP, Guo Q, Tatton WG. CNTF or (-)-deprenyl in immature rats: survival of axotomized facial motoneurons and weight loss. J Neurosci Res 1995;40:564-570.
82. Iwasaki Y, Ikeda K, Shiojima T, Kobayashi T, Tagaya N, Kinoshita M. Deprenyl and pergolide rescue spinal motor neurons from axotomy-induced neuronal death in the neonatal rat. Neurol Res 1996;18:168-170.
83. Buys YM, Trope GE, Tatton WG. (-)-Deprenyl increases the survival of rat retinal ganglion cells after optic nerve crush. Curr Eye Res 1995;14:119-126.
84. Amenta F, Bograni S, Cadel S, Ferrante F, Valsecchi B, Vega JA. Microanatomical changes in the frontal cortex of aged rats: effect of L-deprenyl treatment. Brain Res Bull 1994;34: 125-131.
85. Amenta F, Bongrani S, Cadel S, Ferrante F, Valsecchi B, Zeng YC. Influence of treatment with L-deprenyl on the structure of the cerebellar cortex of aged rats. Mech Ageing Dev 1994;75:157-167.
86. Tatton WG, Ju WY, Holland DP, Tai C, Kwan M. (-)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J Neurochem 1994;63:1572-1575.
87. Tatton WG, Yu P, Salo PT, Holland D, Kwan M. Both pargyline and selegiline reduce the death of immature motoneurons after axotomy [abstract]. Soc Neurosci Abstr 1992;19: 167.
88. Ansari KS, Zhang F, Holland DH, Yu PH, Tatton WG. R(-)-Deprenyl, not its major metabolites, rescue axotomized immature facial motoneurons [abstract]. Soc Neurosci Abstr 1993;19.
89. Tatton WG, Salo PT, Yu PH, Holland DP, Kwan MM, Ansari KS. Both selegiline and pargyline reduce the death of immature motoneurons caused by axotomy [abstract]. Soc Neurosci Abstr 1992;18:47.
90. Mitchell IJ, Lawson S, Moser B, et al. Glutamate-induced apoptosis results in a loss of striatal neurons in the parkinsonian rat. Neuroscience 1994;63:1-5.
91. Bonfoco E, Krainc D, Ankarcrona M, Nicotera P, Lipton SA. Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide/superoxide in cortical cell cultures. Proc Natl Acad Sci USA 1995;92:7162-7166.
92. Portera-Cailliau C, Hedreen JC, Price DL, Koliatsos VE. Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models. J Neurosci 1995;15:3775-3787.
93. Mutoh T, Tokuda A, Marini AM, Fujiki N. 1-Methyl-4-phenylpyridinum kills differentiated PC12 cells with a concomitant change in protein phosphorylation. Brain Res 1994; 661:51-55.
94. Forloni G, Chiesa R, Smiroldo S, et al. Apoptosis mediated neurotoxicity induced by chronic application of beta amyloid fragment 25-35. Neuroreport 1993;4:523-526.
95. Watt JA, Pike CJ, Walencewicz-Wasserman AJ, Cotman CW. Ultrastructural analysis of beta-amyloid-induced apoptosis in cultured hippocampal neurons. Brain Res 1994;661:147-156.
96. Zsnagy I, Steiber J, Jeney F. Induction of age pigment accumulation in the brain cells of young male rats through iron-injection into the cerebrospinal fluid. Gerontology 1995;41: 145-156.
97. Farinelli SE, Greene LA. Cell cycle blockers mimosine, ciclopirox, and deferoxamine prevent the death of PC12 cells and postmitotic sympathetic neurons after removal of trophic support. J Neurosci 1996;16:1150-1162.
98. Gobe GC. Apoptosis in brain and gut tissue of mice fed a seed preparation of the cycad Lepidozamia peroffskyana. Biochem Biophys Res Commun 1994;205:327-333.
99. Muller WE, Schroder HC, Ushijima H, Dapper J, Bormann J. gp120 of HIV-1 induces apoptosis in rat cortical cell cultures: prevention by memantine. Eur J Pharmacol 1992;226:209-214.
100. Walkinshaw G, Waters CM. Induction of apoptosis in catecholaminergic PC12 cells by L-dopa: implications for the treatment of Parkinson's disease. J Clin Invest 1995;95: 2458-2464.
101. Hartley A, Stone JM, Heron C, Cooper JM, Schapira AH. Complex I inhibitors induce dose-dependent apoptosis in PC12 cells: relevance to Parkinson's disease. J Neurochem 1994;63:1987-1990.
102. Koh JY, Cotman CW. Programmed cell death: its possible contribution to neurotoxicity mediated by calcium channel antagonists. Brain Res 1992;587:233-240.
103. Slater AF, Nobel CS, Orrenius S. The role of intracellular oxidants in apoptosis. Biochim Biophys Acta 1995;1271:59-62.
104. Finnegan KT, Karler R. Role for protein synthesis in the neurotoxic effects of methamphetamine in mice and rats. Brain Res 1992;591:160-164.
105. Bonfoco E, Ceccatelli S, Manzo L, Nicotera P. Colchicine induces apoptosis in cerebellar granule cells. Exp Cell Res 1995;218:189-200.
106. Brugg B, Michel PP, Agid Y, Ruberg M. Ceramide induces apoptosis in cultured mesencephalic neurons. J Neurochem 1996;66:733-739.
107. Kobayashi Y, Saheki T, Shinozawa T. Induction of PC12 cell death, apoptosis, by a sialoglycopeptide from bovine brain. Biochem Biophys Res Commun 1994;203:1554-1559.
108. Dessi F, Pollard H, Moreau J, Ben Ari Y, Charriaut-Marlangue C. Cytosine arabinoside induces apoptosis in cerebellar neurons in culture. J Neurochem 1995;64:1980-1987.
109. Ziv I, Melamed E, Nardi N, et al. Dopamine induces apoptosis-like cell death in cultured chick sympathetic neurons. Neurosci Lett 1994;170:136-140.
110. Batistatou A, Greene LA. Internucleosomal DNA cleavage and neuronal cell survival/death. J Cell Biol 1993;122:523-532.
111. Darzynkiewicz Z, Bruno S, Del Bino G, et al. Features of apoptotic cells measured by flow cytometry. Cytometry 1992; 13:795-808.
112. Deckwerth TL, Johnson EM, Jr. Temporal analysis of events associated with programmed cell death (apoptosis) of sympathetic neurons deprived of nerve growth factor. J Cell Biol 1993;123:1207-1222.
113. Anglade P, Michel P, Marquez J, et al. Apoptotic degeneration of nigral dopaminergic neurons in Parkinson's disease. Abs Soc Neurosci 1995;21:1250.
114. Cotman CW, Anderson AJ. A potential role for apoptosis in neurodegeneration and Alzheimer's disease. Mol Neurobiol 1995;10:19-45.
115. Anderson AJ, Su JH, Cotman CW. DNA damage and apoptosis in Alzheimer's disease: colocalization with c-Jun immunoreactivity, relationship to brain area and the effect of post-mortem delay. J Neurosci 1996;16:1710-1719.
116. Su JH, Anderson AJ, Cummings BJ, Cotman CW. Immunohistochemical evidence for apoptosis in Alzheimer's disease. Neuroreport 1994;5:2529-2533.
117. Lassmann H, Bancher C, Breitschopf H, et al. Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ. Acta Neuropathol Ber 1995;89:35-41.
118. Cotman CW, Whittemore ER, Watt JA, Anderson AJ, Loo DT. Possible role of apoptosis in Alzheimer's disease. Ann NY Acad Sci 1994;747:36-49.
119. Dragunow M, Faull RL, Lawlor P, et al. In situ evidence for DNA fragmentation in Huntington's disease striatum and Alzheimer's disease temporal lobes. Neuroreport 1995;6: 1053-1057.
120. Steinberg RH. Survival factors in retinal degenerations. Curr Opin Neurobiol 1994;4:515-524.
121. Tso MO, Zhang C, Abler AS, et al. Apoptosis leads to photoreceptor degeneration in inherited retinal dystrophy of RCS rats. Invest Ophthalmol Vis Sci 1994;35:2693-2699.
122. Yoshiyama Y, Yamada T, Asanuma K, Asahi T. Apoptosis related antigen, Le(Y) and nick-end labeling are positive in spinal motor neurons in amyotrophic lateral sclerosis. Acta Neuropathol (Berl) 1994;88:207-211.
123. Thomas LB, Gates DJ, Richfield EK, TF OB, Schweitzer JB, Steindler DA. DNA end labeling (TUNEL) in Huntington's disease and other neuropathological conditions. Exp Neurol 1995;133:265-272.
124. Petito CK, Roberts B. Evidence of apoptotic cell death in HIV encephalitis. Am J Pathol 1995;146:1121-1130.
125. Migheli A, Cavalla P, Marino S, Schiffer D. A study of apoptosis in normal and pathologic nervous tissue after in situ end-labeling of DNA strand breaks. J Neuropathol Exp Neurol 1994;53:606-616.
126. Petito CK, Roberts B. Effect of postmortem interval on in situ end-labelling of DNA oligonucleosomes. J Neuropathol Exp Neurol 1995;54:761-765.
127. Charriaut-Mariangue C, Ben-Ari Y. A cautionary note on the use of the TUNEL stain to determine apoptosis. Neuroreport 1995;7:61-64.
128. Raff MC, Barres BA, Burne JF, Coles HS, Ishizaki Y, Jacobson MD. Programmed cell death and the control of cell survival: lessons from the nervous system. Science 1993;262: 695-700.
129. Seniuk-Tatton NA, Henderson JT, Roder JC. Neurons express ciliary neurotrophic factor mRNA in the early postnatal and adult rat brain. J Neurosci Res 1995;41:663-676.
130. Seniuk NA. Neurotrophic factors: role in peripheral neuron survival and axonal regrowth following injury. J Microvasc Surg 1992;8:399-404.
131. Hatten ME, Liem RKH, Shelanski ML, Mason CA. Astroglia in CNS injury. Glia 1991;4:233-243.
132. Bredesen DE. Neural apoptosis. Ann Neurol 1995;38:839-851.
133. Kroemer G, Petit P, Xamzami N, Vayssierre JL, Mignotte B. The biochemistry of programmed cell death. FASEB J 1995; 9:1277-1287.
134. Oltvai ZN, Korsmeyer SJ. Checkpoints of dueling dimers foil death wishes. Cell 1994;79:189-192.
135. Takahashi A, Earnshaw WC. ICE-related proteases in apoptosis. Curr Opin Genet Dev 1996;6:50-55.
136. Dragunow M, Preston K. The role of inducible transcription factors in apoptotic nerve cell death. Brain Res Rev 1995;21: 1-28.
137. Schlingensiepen KH, Wollnik F, Kunst M, Schlingensiepen R, Herdegen T, Brysch W. The role of Jun transcription factor expression and phosphorylation in neuronal differentiation, neuronal cell death, and plastic adaptations in vivo. Cell Mol Neurobiol 1994;14:487-505.
138. Ham J, Babij C, Whitfield J, et al. A c-Jun dominant negative mutant protects sympathetic neurons against programmed cell death. Neuron 1995;14:927-939.
139. Rothstein JD, Bristol LA, Hosler B, Brown RH, Jr, Kuncl RW. Chronic inhibition of superoxide dismutase produces apoptotic death of spinal neurons. Proc Natl Acad Sci USA 1994;91:4155-4159.
140. Troy CM, Shelanski ML. Down-regulation of copper/zinc superoxide dismutase causes apoptotic death in PC12 neuronal cells. Proc Natl Acad Sci USA 1994;91:6384-6387.
141. Nicholls DG, Ferguson SJ. Bioenergetics 2. London: Academic, 1992.
142. +, and volume inside cultured adult rabbit cardiac myocytes during chemical hypoxia: a multiparameter digitized confocal microscopic study. Biophys J 1994;66:942-952.
143. Richter C, Kass GEN. Oxidative stress in mitochondria: its relationship to cellular calcium homeostasis, cell death, proliferation, and differentiation. Chem Biol Interact 1991;77:1-23.
144. + in the oxidative stress-induced dissipation of the mitochondrial membrane potential. J Biol Chem 1994;269:14546-14552.
145. +)-dependent permeabilization of the inner mitochondrial membrane by 4,4′-diisothicyanatostilbene-2,2′-isulfonic acid (DIDS). Biochim Biophys Acta 1994;1188:93-100.
146. Beal MF. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann Neurol 1992;31:119-130.
147. Beal MF, Hyman T, Koroshetz W. Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? Trends Neurosci 1993;16:125-131.
148. Frim DM, Simpson J, Uhler TA, et al. Striatal degeneration induced by mitochondrial blockade is prevented by biologically delivered NGF. J Neurosci Res 1993;35:452-458.
149. + homeostasis, and cell injury, but not ATP depletion in hippocampal neurons deprived of glucose. Exp Neurol 1993;121:1-13.
150. Mutisya EM, Bowling AC, Beal MF. Cortical cytochrome oxidase activity is reduced in Alzheimer's disease. J Neurochem 1994;63:2179-2184.
151. Schulze-Osthoff K, Bakker AC, Vanhaesebroeck B, Beyaert R, Jacob WA, Fiers W. Cytotoxic activity of tumor necrosis factor is mediated by early damage of mitochondrial functions. J Biol Chem 1992;267:5317-5323.
152. Tipton KF, Singer TP. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J Neurochem 1993;61:1191-1207.
153. Brouillet E, Jenkins BG, Hyman BT, et al. Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid. J Neurochem 1993;60:356-359.
154. Baixera E, Bosca L, Stauber C, Gonzalez A, Gonzalo JA, Martinez A. From apoptosis to autoimmunity: insights from signaling pathways leading to proliferation or programmed cell death. Immunol Rev 1994;142:53-91.
155. +: their relationship to apoptosis and oncogenesis. FEBS Lett 1993;325: 104-107.
156. Jacobson MD, Burne JF, King MP, Miyashita T, Reed JC, Raff MC. Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA. Nature 1993;361:365-369.
157. Jacobson MD, Burne JF, King MP, Miyashita T, Reed JC, Raff MC. Apoptosis and bcl-2 protein in cells without mitochondrial DNA. Nature 1993;361:365-368.
158. Richter C, Gogvadze V, Laffranchi R, et al. Oxidants in mitochondria: from physiology to diseases. Biochim Biophys Acta 1995;1271:67-74.
159. Newmeyer DD, Farschon DM, Reed JC. Cell-free apoptosis in Xenopus egg extracts: inhibition by bcl-2 and requirement for an organelle fraction enriched in mitochondria. Cell 1994; 79:353-364.
160. Zamzami N, Marchetti P, Castedo M, et al. Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death. J Exp Med 1995;182:367-377.
161. Zamzami N, Marchetti P, Castedo M, et al. Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. J Exp Med 1995; 181:1661-1672.
162. Zamzami N, Marchetti P, Castedo M, et al. Inhibitors of permeability transition interfere with the disruption of mitochondrial transmembrane potential during apoptosis. FEBS Lett 1996;384:53-57.
163. Vayssiere JL, Petit PX, Risler Y, Mignotte B. Commitment to apoptosis is associated with changes in mitochondrial biogenesis and activity in cell lines conditionally immortalized with simian virus 40. Proc Natl Acad Sci USA 1994;91: 11752-11756.
164. Petit PX, Lecoeur H, Zorn E, Dauguet C, Mignotte B, Gougeon ML. Alterations in mitochondrial structure and function are early events of dexamethasone-induced thymocyte apoptosis. J Cell Biol 1995;130:157-167.
165. Tatton WG, Ju WJH, Wadia J, Tatton NA. Reduction of neuronal apoptosis by small molecules: promise for new approaches to neurological therapy. In: Olanow W, Youdim M, Jenner P, eds. Neuroprotection and neurodegeneration. New York: Academic, 1996:209-229.
166. Zoratti M, Szabo I. The mitochondrial permeability transition. Biochim Biophys Acta 1995;1241:139-176.
167. + in vivo. Eur J Pharmacol 1993;243:241-247.
168. Chiueh CC, Huang SJ, Murphy DL. Suppression of hydroxyl radical formation by MAO inhibitors: a novel possible neuroprotective mechanism in dopaminergic neurotoxicity. J Neural Trans Suppl 1994;41:189-196.
169. Chiueh CC, Wu RM, Mohanakumar KP, et al. In vivo generation of hydroxyl radicals and MPTP-induced dopaminergic toxicity in the basal ganglia. Ann NY Acad Sci 1994;738:25-36.
170. + toxicity by deprenyl (selegiline). Ann NY Acad Sci 1994;738:214-221.
171. Knoll J. The striatal dopamine dependency of life span in male rats: longevity study with (-)deprenyl. Mech Ageing Dev 1988;46:237-262.
172. Carrillo MC, Kanai S, Nokubo M, Kitani K. (-)deprenyl induces activities of both superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats. Life Sci 1991;48:517-521.
173. Carrillo MC, Kitani K, Kanai S, Sato Y, Ivy GO. The ability of (-)deprenyl to increase superoxide dismutase activities in the rat is tissue and brain region selective. Life Sci 1992;50: 1985-1992.
174. Carrillo MC, Kanai S, Sato Y, Nokubo M, Ivy GO, Kitani K. The optimal dosage of (-)deprenyl for increasing superoxide dismutase activities in several brain regions decreases with age in male Fischer 344 rats. Life Sci 1993;52:1925-1934.
175. Carrillo MC, Ivy GO, Milgram NW, Head E, Wu P, Kitani K. (-)Deprenyl increases activities of superoxide dismutase (SOD) in striatum of dog brain. Life Sci 1994;54:1483-1489.
176. Lai CT, Zuo DM, Yu PH. Is brain superoxide dismutase activity increased following chronic treatment with L-deprenyl? J Neural Transm Suppl 1994;41:221-229.
177. Thiffault C, Aumont N, Quirion R, Poirier J. Effect of MPTP and L-deprenyl on antioxidant enzymes and lipid peroxidation levels in mouse brain. J Neurochem 1995;65:2725-2733.
178. Kushleika J, Checkoway H, Woods JS, et al. Selegiline and lymphocyte superoxide dismutase activities in Parkinson's disease. Ann Neurol 1996;39:378-381.
179. Biagini G, Zoli M, Fuxe K, Agnati LF. L-Deprenyl increases GFAP immunoreactivity selectively in activated astrocytes in rat brain. Neuroreport 1993;4:955-958.
180. Biagini G, Frasoldati A, Fuxe K, Agnati LF. The concept of astrocyte-kinetic drug in the treatment of neurodegenerative diseases: evidence for L-deprenyl-induced activation of reactive astrocytes. Neurochem Int 1994;25:17-22.
181. Li XM, Qi J, Juorio AV, Boulton AA. Reduction in glial fibrillary acidic protein messenger RNA abundance induced by (-)-deprenyl and other monoamine oxidase B-inhibitors in C6 glioma cells. J Neurochem 1993;61:1573-1576.
182. Seniuk NA, Henderson JT, Tatton WG, Roder JC. Increased CNTF gene expression in process-bearing astrocytes following injury is augmented by R(-)-deprenyl. J Neurosci Res 1994;37:278-286.
183. Ekblom J, Jossan SS, Ebendal T, Soderstrom S, Oreland L, Aquilonius SM. mRNA expression of neurotrophins and members of the trk family in the rat brain after treatment with L-deprenyl. Acta Neurol Scand 1994;89:147-148.
184. Li XM, Juorio AV, Paterson IA, Zhu MY, Boulton AA. Specific irreversible monoamine oxidase-B inhibitors stimulate gene expression of aromatic L-amino acid decarboxylase in PC12-cells. J Neurochem 1992;59:2324-2327.
185. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334-336.
186. Monaghan P, Robertson D, Amos AS, Dyer MJS, Mason DY, Greaves MF. Ultrastructural localization of bcl-2 protein. J Histochem Cytochem 1992;40:1819-1825.
187. Nakai M, Takeda A, Cleary ML, Endo T. The bcl-2 protein is inserted into the outer membrane but not into the inner membrane of rat liver mitochondria in vitro. Biochem Biophys Res Commun 1993;196:233-239.
188. Janiak F, Leber B, Andrews DW. Assembly of bcl-2 into microsomal and outer mitochondrial membranes. Biol Chem 1994;269:9842-9849.
189. Lithgow T, van Driel R, Bertram JF, Strasser A. The protein product of the oncogene bcl-2 is a component of the nuclear envelope, the endoplasmic reticulum, and the outer mitochondrial membrane. Cell Growth Differ 1994;5:411-417.
190. Smets LA, Van den Berg J, Acton D, Top B, Van Rooij H, Verwijs-Janssen M. Bcl-2 expression and mitochondrial activity in leukemic cells with different sensitivity to glucocorticoid-induced apoptosis. Blood 1994;84:1613-1619.
191. Wolvetang EJ, Johnson ICL, Krauer K, Ralph SJ, Linnane AW. Mitochondrial respiratory chain inhibitors induce apoptosis. FEBS Lett 1994;339:40-44.
192. Hockenbery DM, Oltvai ZN, Yin XM, Milliman CL, Korsmeyer SJ. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 1993;75:241-251.
193. Hennet TG, Bertoni G, Richter C, Peterhans E. Expression of bcl-2 protein enhances the survival of mouse fibrosarcoid cells in tumor necrosis factor-mediated cytotoxicity. Cancer Res 1993;53:1456-1460.
194. Tatton W, Ju W, Wadia J, et al. (-)-Deprenyl reduces neuronal apoptosis by maintaining bcl-2 synthesis and mitochondrial membrane potential [abstract]. Mov Disord 1994;9:4.
195. Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994;124:1-6.
196. Richter C, Schweizer M, Cossarizza A, Franceschi C. Control of apoptosis by the cellular ATP level. FEBS Lett. 1996;378: 107-110.
197. Gotz ME, Dirr A, Burger R, Rausch WD, Riederer P. High dose selegiline augments striatal ubiquinol in mouse: an indication of decreased oxidative stress or of interference with mitochondrial respiration? A pilot study. J Neural Transm Suppl 1995;46:149-156.
198. Greenlund LJS, Deckwerth TL, Johnson EM. Superoxide dismutase delays neuronal apoptosis: a role for reactive oxygen species in programmed neuronal death. Neuron 1995;14: 303-315.
199. Johnson EM, Greenlund LJS, Akins PT, Hsu CY. Neuronal apoptosis: current understanding of molecular mechanisms and potential role in ischemic brain injury. J Neurotrauma 1995;12:843-852.
200. Slater AFG, Stefan C, Nobel I, vandenDobbelsteen DJ, Orrenius S. Signalling mechanisms and oxidative stress in apoptosis. Toxicol Lett 1995;82-3:149-153.
201. Burke JR, Enghild JJ, Martin ME, et al. Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH. Nature Med 1996;2:347-350.
202. Tong L, Perez-Polo JR. Transcription factor DNA binding activity in PC12 cells undergoing apoptosis after glucose deprivation. Neurosci Lett 1995;191:137-140.
203. Talley AK, Dewhurst S, Perry SW, et al. Tumor necrosis factor alpha-induced apoptosis in human neuronal cells: protection by the antioxidant N-acetylcysteine and the genes bcl-2 and crmA. Mol Cell Biol 1995;15:2359-2366.
204. Heinonen EH, Anttila MI, Lammintausta RA. Pharmacokinetic aspects of L-deprenyl (selegiline) and its metabolites. Clin Pharmacol Ther 1994;56:742-749.
205. Magyar K, Lengyel J, Szatmari I, Gaal J. The distribution of orally administered (-)-deprenyl propynyl-14C and (-)-deprenyl-phenyl-3H in rat brain. Prog Brain Res 1995; 106:143-153.